Agreement Between Human Horizons, Wuxi Weifu e-Drive Technology and Protean Electric Will Deliver Mass Produced In-Wheel Motors for Intelligent Connected Vehicles
Human Horizons, the mobility technology innovator, Protean Electric Ltd, the automotive technology company, and Wuxi Weifu e-Drive Technology Ltd. (“WFDT”) are pleased to announce their memorandum of strategic co-operation to develop and manufacture in-wheel motors for the next generation of intelligent connected vehicles. The co-operation brings together some of the most technologically advanced and innovative companies in the automotive sector. A dedicated team and production facility will be created in China to deliver in-wheel motors at scale, simplifying production systems, reducing development lead times and accelerating the benefits that in-wheel motors bring to the market for future transport solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181218005879/en/
Mark Stanton, CTO of Human Horizons and Wang Xiaodong, Deputy Chairman of Weifu High-Technology Group Ltd signed the memorandum of strategic cooperation on behalf of all parties. (Photo: Business Wire)
Ding Lei, Chairman of Human Horizons said: "The cooperation between WFDT, Protean Electric and Human Horizons using in-wheel motor technology is only the beginning of our long-term strategic cooperation. We plan to start with cars and over time develop further innovative mobility solutions. The advanced drive system and the unique location of the in-wheel motor in the vehicle delivers a game changing driving experience and powerful data collection solution, integrated into the intelligent car. The potential for cooperation is unlimited.”
"Human Horizons are one of the most exciting companies working in future mobility today. They have rich automotive engineering experience and are one of the strongest and most innovative teams in the industry,” said Chen Xuejun, Chairman of Weifu Group. “With more than 30 years’ of experience working across the industry, Weifu Group has deep experience in auto parts production, continuous manufacturing improvement, mature supply chain resources and the management and delivery of sustained investment in new technologies. ProteanDrive advanced in-wheel motor technology will enable a truly strategic partnership for WFDT, Protean Electric and Human Horizons."
KwokYin Chan, CEO of Protean Electric, said: "We are delighted to see that the opportunities offered by our in-wheel electric drive technology are being used by customers to develop some of the most innovative transport solutions in the world. Our continuous commitment to innovation ensures that we are able to provide solutions tailored to the needs of our customers, both now and for the future.”
About Human Horizons
Human Horizons is an innovative technology company committed to future intelligent mobility with “3-Smart” (Smart Vehicle, Smart Transportation and Smart City) as its strategy.
Human Horizons upholds a human-oriented philosophy; initiated from human needs and based on human intelligence. Human Horizons will build on research and development for innovative and leading intelligent mobility technologies and the industrialization of future-oriented smart vehicles to further plan smart transportations, and contribute to the development of smart cities and finally redefine human mobility.
About Wuxi Weifu e-Drive Technology
Wuxi Weifu e-Drive Technology Co., Ltd. is the joint venture formed by Weifu Group and Protean Electric Ltd, for the manufacture of the ProteanDrive Pd18. In China the joint venture focuses on customer application engineering and manufacturing process engineering. Under the leadership of Protean’s technology centre in the UK, the joint venture supports product development and continuous engineering of in-wheel motor products.
Weifu High Technology Group Co., Ltd. (000581.SZ) (“Weifu Group”) is an automotive component manufacturer, and one of the Top 30 Automotive Enterprises. Operating since 1958 in China, Weifu Group leads in automotive fuel in-take and exhaust systems. With 10 wholly owned and majority owned subsidiaries including 2 joint ventures, and one JV with minority interest. Weifu Group has international presence in the US, Middle East and Southeast Asia. Weifu Group is a profitable Shenzhen Stock Exchange listed company, with 2017 revenue exceeding RMB 9 billion, and total assets exceeding RMB 20 billion (approx. $3 billion).
About Protean Electric Ltd
Protean Electric Ltd is a leading automotive technology company that designs, develops and manufactures ProteanDrive, a fully integrated in-wheel drive solution. Protean Electric’s technology is strategically positioned to play a major role in the hybrid and electric vehicle market by offering a combination of packaging advantages, new vehicle design opportunities, performance benefits and cost savings.
Using a scalable and patented sub-motor architecture, ProteanDrive products provide the power and torque required to propel all hybrid and electric vehicle classes. Protean maintains operations in the United Kingdom, China and the USA, with its manufacturing plant at Tianjin, China. For more information, visit www.proteanelectric.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181218005879/en/
Contact information
Media Contacts:
Human Horizons：
Tao Jin
tao_jin@human-horizons.com
Wuxi
Weifu e-Drive：
Yi Wang
Yi.wang@weifu.com.cn
Protean
Electric：
Robyn Hughes
Robyn.hughes@proteanelectric.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com